MedPath
Found 22 clinical trials|View Analysis
Sort by:

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Phase 2
Recruiting
Conditions
Resectable Sarcoma
Interventions
First Posted Date
2021-07-20
Last Posted Date
2023-03-03
Lead Sponsor
Institut Bergonié
Target Recruit Count
66
Registration Number
NCT04968106
Locations
🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

Institut Curie, Paris, France

and more 1 locations

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

Phase 2
Withdrawn
Conditions
Advanced Neuroendocrine Neoplasm
Carcinoid Syndrome
Interventions
Biological: Retifanlimab
Drug: Telotristat Ethyl
First Posted Date
2021-03-02
Last Posted Date
2021-09-29
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT04776876

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Phase 1
Completed
Conditions
Non Small Cell Lung Cancer
Castration Resistant Prostate Cancer
Colorectal Cancer
Triple Negative Breast Cancer
Gastric/ Gastroesophageal Junction
Squamous Carcinoma of the Anal Canal
Squamous Cell Carcinoma of Head and Neck
Pancreatic Ductal Adenocarcinoma
Ovarian Cancer
Bladder Cancer
Interventions
Drug: INCB106385
Drug: INCMGA00012
First Posted Date
2020-10-08
Last Posted Date
2024-03-08
Lead Sponsor
Incyte Corporation
Target Recruit Count
54
Registration Number
NCT04580485
Locations
🇧🇪

Cliniques Universitaires Ucl Saint-Luc, Brussels, Belgium

🇺🇸

Cedars-Sinai Medical Center, West Hollywood, California, United States

🇺🇸

University of Maryland-Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 24 locations

Randomized Phase II Trial of a PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy(RHAPSODY)

Phase 2
Not yet recruiting
Conditions
Esophageal Cancer
Interventions
Drug: INCMGA00012
First Posted Date
2020-07-31
Last Posted Date
2020-07-31
Lead Sponsor
Asan Medical Center
Target Recruit Count
110
Registration Number
NCT04494009

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Phase 1
Recruiting
Conditions
Cancer of the Head and Neck
Interventions
Drug: INCMGA00012
Drug: INCAGN01876
Biological: DPV-001
First Posted Date
2020-07-14
Last Posted Date
2024-06-21
Lead Sponsor
Providence Health & Services
Target Recruit Count
56
Registration Number
NCT04470024
Locations
🇺🇸

Portland Providence Medical Center, Portland, Oregon, United States

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Phase 2
Recruiting
Conditions
Endometrial Cancer
Interventions
First Posted Date
2020-07-09
Last Posted Date
2024-06-24
Lead Sponsor
Incyte Corporation
Target Recruit Count
300
Registration Number
NCT04463771
Locations
🇺🇸

Advent Health Medical Group-Orlando 2501, Orlando, Florida, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, United States

🇺🇸

Alaska Womens Cancer Care Akwcc, Anchorage, Alaska, United States

and more 62 locations

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Phase 2
Recruiting
Conditions
Prognostic Stage IV Breast Cancer AJCC v8
Triple-negative Breast Cancer
Locally Advanced Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Carcinoma
Interventions
Biological: Pelareorep
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Biological: Retifanlimab
First Posted Date
2020-06-24
Last Posted Date
2024-04-02
Lead Sponsor
Mridula George, MD
Target Recruit Count
25
Registration Number
NCT04445844
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

The Ohio State University Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio, United States

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Phase 2
Active, not recruiting
Conditions
Well-differentiated/Dedifferentiated Liposarcoma
Interventions
Drug: INCMGA00012
Drug: Palbociclib
First Posted Date
2020-06-19
Last Posted Date
2024-08-21
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
42
Registration Number
NCT04438824
Locations
🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Phase 1
Active, not recruiting
Conditions
Melanoma
Interventions
Drug: INCAGN02385
Drug: INCAGN02390
Drug: INCMGA00012.
First Posted Date
2020-05-01
Last Posted Date
2024-10-02
Lead Sponsor
Incyte Corporation
Target Recruit Count
61
Registration Number
NCT04370704
Locations
🇺🇸

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States

🇦🇺

Box Hill Hospital, Box Hill, Victoria, Australia

🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

and more 14 locations

Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)

Phase 2
Conditions
Penile Cancer
Interventions
Drug: INCMGA0012
First Posted Date
2020-01-18
Last Posted Date
2023-01-19
Lead Sponsor
MedSIR
Target Recruit Count
18
Registration Number
NCT04231981
Locations
🇮🇹

IRCCS Ospedale San Raffaele, Milano, Italy

🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano., Milan, Italy

🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath